Your browser doesn't support javascript.
loading
Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Chapeau, Emilie A; Sansregret, Laurent; Galli, Giorgio G; Chène, Patrick; Wartmann, Markus; Mourikis, Thanos P; Jaaks, Patricia; Baltschukat, Sabrina; Barbosa, Ines A M; Bauer, Daniel; Brachmann, Saskia M; Delaunay, Clara; Estadieu, Claire; Faris, Jason E; Furet, Pascal; Harlfinger, Stefanie; Hueber, Andreas; Jiménez Núñez, Eloísa; Kodack, David P; Mandon, Emeline; Martin, Typhaine; Mesrouze, Yannick; Romanet, Vincent; Scheufler, Clemens; Sellner, Holger; Stamm, Christelle; Sterker, Dario; Tordella, Luca; Hofmann, Francesco; Soldermann, Nicolas; Schmelzle, Tobias.
Afiliación
  • Chapeau EA; Novartis BioMedical Research, Basel, Switzerland. emilie.chapeau@novartis.com.
  • Sansregret L; Novartis BioMedical Research, Basel, Switzerland.
  • Galli GG; Novartis BioMedical Research, Basel, Switzerland.
  • Chène P; Novartis BioMedical Research, Basel, Switzerland.
  • Wartmann M; Novartis BioMedical Research, Basel, Switzerland.
  • Mourikis TP; Novartis BioMedical Research, Basel, Switzerland.
  • Jaaks P; Novartis BioMedical Research, Basel, Switzerland.
  • Baltschukat S; Novartis BioMedical Research, Basel, Switzerland.
  • Barbosa IAM; Novartis BioMedical Research, Basel, Switzerland.
  • Bauer D; Novartis BioMedical Research, Basel, Switzerland.
  • Brachmann SM; Novartis BioMedical Research, Basel, Switzerland.
  • Delaunay C; Novartis BioMedical Research, Basel, Switzerland.
  • Estadieu C; Novartis BioMedical Research, Basel, Switzerland.
  • Faris JE; Novartis BioMedical Research, Cambridge, MA, USA.
  • Furet P; Novartis BioMedical Research, Basel, Switzerland.
  • Harlfinger S; Novartis BioMedical Research, Basel, Switzerland.
  • Hueber A; AstraZeneca, Oncology R&D, Cambridge, UK.
  • Jiménez Núñez E; Novartis BioMedical Research, Basel, Switzerland.
  • Kodack DP; Novartis BioMedical Research, Basel, Switzerland.
  • Mandon E; Novartis BioMedical Research, Cambridge, MA, USA.
  • Martin T; Novartis BioMedical Research, Basel, Switzerland.
  • Mesrouze Y; Novartis BioMedical Research, Basel, Switzerland.
  • Romanet V; Novartis BioMedical Research, Basel, Switzerland.
  • Scheufler C; Novartis BioMedical Research, Basel, Switzerland.
  • Sellner H; Novartis BioMedical Research, Basel, Switzerland.
  • Stamm C; Novartis BioMedical Research, Basel, Switzerland.
  • Sterker D; Novartis BioMedical Research, Basel, Switzerland.
  • Tordella L; Novartis BioMedical Research, Basel, Switzerland.
  • Hofmann F; Novartis BioMedical Research, Basel, Switzerland.
  • Soldermann N; Novartis BioMedical Research, Basel, Switzerland.
  • Schmelzle T; Pierre Fabre Group, R&D Medical Care, Toulouse, France.
Nat Cancer ; 2024 Jun 17.
Article en En | MEDLINE | ID: mdl-38886525
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Nat Cancer Año: 2024 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Nat Cancer Año: 2024 Tipo del documento: Article País de afiliación: Suiza